Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends

This research aims to explore the historical evolution, key research areas, and new trends in PD-1/PD-L1 immunotherapy for hepatocellular carcinoma (HCC) over the last twenty years, focusing on structural and temporal dynamics. The Web of Science Core Collection (WoSCC) database was used to gather studies on PD-1/PD-L1 immunotherapy for HCC.CiteSpace and HistCite were utilized for a bibliometric analysis to investigate the historical progression, research evolution, and emerging trends in this area. In the last two decades, 2804 papers on PD-1/PD-L1 immunotherapy in HCC have been published, comprising 541 reviews and contributions from 13,796 authors across 2,659 institutions. Since 2014, the number of annual publications has significantly increased, with extensive international collaboration. Several active research topics have emerged, covering 72 disciplines, generating 561 keywords, and 1,199 articles that experienced citation bursts. Cluster analysis of keywords revealed five emerging subfields: lenvatinib, immune escape, immne checkpoint inhibitors, prognostic models, and tumor microenvironment. According to the "Timeline visualization of references," classic topics include CMTM6, regulatory T cells, liver transplantation, and bioinformatics analysis, while emerging topics include prognosis, lenvatinib, transarterial chemoembolization, hepatic arterial infusion chemotherapy, and single-cell RNA sequencing. This study sheds light on the current status and developing trends in PD-1/PD-L1 immunotherapy research for HCC, offering researchers valuable insights to identify crucial areas and explore new research directions.

Authors

Institutions

Publication Details

Journal
Human Vaccines & Immunotherapeutics
Published
2025-08-17
DOI
https://doi.org/10.1080/21645515.2025.2540143
Citations
1
Primary Topic
Cancer Immunotherapy and Biomarkers
Type
article
Field-Weighted Citation Impact
1.05
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends

Aimitaji Abulaiti, Tuerganaili Aji, Talaiti Tuergan, Yingmei Shao
1 citations
Human Vaccines & Immunotherapeutics
Cancer Immunotherapy and Biomarkers
1.05
article

Structural and temporal dynamics analysis of PD-1/PD-L1 immunotherapy in hepatocellular carcinoma: History, research hotspots, and emerging trends

Aimitaji Abulaiti, Tuerganaili Aji, Talaiti Tuergan, Yingmei Shao
article en
1 citations

Abstract

This research aims to explore the historical evolution, key research areas, and new trends in PD-1/PD-L1 immunotherapy for hepatocellular carcinoma (HCC) over the last twenty years, focusing on structural and temporal dynamics. The Web of Science Core Collection (WoSCC) database was used to gather studies on PD-1/PD-L1 immunotherapy for HCC.CiteSpace and HistCite were utilized for a bibliometric analysis to investigate the historical progression, research evolution, and emerging trends in this area. In the last two decades, 2804 papers on PD-1/PD-L1 immunotherapy in HCC have been published, comprising 541 reviews and contributions from 13,796 authors across 2,659 institutions. Since 2014, the number of annual publications has significantly increased, with extensive international collaboration. Several active research topics have emerged, covering 72 disciplines, generating 561 keywords, and 1,199 articles that experienced citation bursts. Cluster analysis of keywords revealed five emerging subfields: lenvatinib, immune escape, immne checkpoint inhibitors, prognostic models, and tumor microenvironment. According to the "Timeline visualization of references," classic topics include CMTM6, regulatory T cells, liver transplantation, and bioinformatics analysis, while emerging topics include prognosis, lenvatinib, transarterial chemoembolization, hepatic arterial infusion chemotherapy, and single-cell RNA sequencing. This study sheds light on the current status and developing trends in PD-1/PD-L1 immunotherapy research for HCC, offering researchers valuable insights to identify crucial areas and explore new research directions.

Human Vaccines & ImmunotherapeuticsVol. 21(1)
Xinjiang Medical University (CN), First Affiliated Hospital of Xinjiang Medical University (CN)
Good health and well-being
Openalex Percentile: Top 19%
Cancer Immunotherapy and Biomarkers
1.05
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.